Sign up Australia
Proactive Investors - Run By Investors For Investors

Q BioMed's pipeline boosted as tech partner gets funding for glaucoma therapeutic research

Partner Mannin Research Inc has received funding to carry out a proof of concept study for the treatment
Q BioMed's pipeline boosted as tech partner gets funding for glaucoma therapeutic research
The eyes have it...Mannin is researching a new therapeutic for glaucoma

Biotech accelerator firm Q BioMed Inc (OTCMKTS:QBIO) announced further progress in its bid to expand its pipeline.

Partner Mannin Research Inc has received funding to carry out a proof of concept study for a new therapeutic for eye condition  glaucoma, in which the optic nerve is damaged.

The R&D funding comes from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) and the number of potential patients demanding better treatments make this a multi-billion-dollar opportunity, says QBiomed.

The company has licensed the Mannin Tie2 technology, and is collaboratively developing the Tie2 platform for glaucoma, and other indications.

It has the potential to treat several additional, vascular related diseases, such as acute kidney injury, and cardiorenal syndrome.

"As our understanding about the Angiopoietin-Tie2 system grows, I am very excited about the clinical therapeutic possibilities," said Dr. Sarah Quaggin from Mannin.

The new biologic would be an additional product to the Mannin Tie2 pipeline.

Meanwhile,  Q BioMed said development of the MAN-01 small molecule for the treatment of primary open-angle glaucoma continues on-pace and is now at a point where the most active candidates will be selected for final testing and optimization as a soluble, topical eye drop that permeates well into the eye.

It is anticipated that pre-clinical IND enabling studies will begin in the second quarter of 2018.

Shares in New York eased 0.27% to US$3.69.



Giles_55af4ddca6481.jpg
Why Invest In Q BioMed Inc? Read More Here

Register here to be notified of future QBIO Company articles
View full QBIO profile View Profile

Q BioMed Inc Timeline

Related Articles

diagram of the human microbiome
September 13 2017
OptiBiotix is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin
the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
ventripoint_device.png
June 22 2017
The device can give accurate and rapid volumetric information about all four chambers of the heart

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use